Jeannie Hoffman-Censits

13PUBLICATIONS
133CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

|Apr 19, 2026
Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.

|Jan 07, 2026
Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma.

Akhilesh Mishra, Ajay Kumar Sharma, Kuldeep Gupta

|Nov 03, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

David H Aggen, Meredith McKean, Jean H Hoffman-Censits

|Sep 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

|Aug 19, 2025
Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin-Related Dermatologic Events in Patients with Advanced Urothelial Cancer.

Evangelia Vlachou, Burles A Johnson, David J McConkey

Pageof 3

Frequent Collaborators

3 joint publications

Evan J Lipson

3 joint publications

Mari Nakazawa

3 joint publications

Soren Charmsaz

3 joint publications

Christopher Thoburn